logo

Quick Facts

Share

Gilead Sciences Inc. (GILD) said that the U.S. Food and Drug Administration approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC...

Qiming Venture Partners said that its portfolio company Structure Therapeutics Inc. (GPCR), a clinical stage global biopharmaceutical company focusing on novel oral small molecule therapeutics, successfully debuts on Nasdaq on February 3 Beijing Time. It issued at $15.00 per ADS, opened at $25.00 per...

Aearo and 3M (MMM) Friday announced an intend to continue to engage in mediation discussions toward a global resolution. Aearo and 3M will try to find a path forward toward a prompt and complete resolution for all parties. The companies said the efforts to resolve ongoing Combat Arms earplugs litigation...

Personalis Inc. (PSNL) said that it signed a new agreement with Moderna Inc. (MRNA) to continue using the Personalis NeXT Platform as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck & Co. The platform,...

AlerisLife Inc. (ALR) Friday announced a definitive agreement with ABP Acquisition LLC by which ABP will acquire ALR common stock for $1.31 per share in cash. The offered price represents an 85 percent premium to the average trading price. The total consideration is approximately $43.8 million. The transaction...

Intesa Sanpaolo (ISNPY.PK, IITSF.PK) reported fourth quarter net income of 1.07 billion euros compared with 179 million euros, a year ago. Net interest income was 3.06 billion euros, up 56.7% compared with 1.95 billion euros, last year. The Group's net income for 2022 was 5.50 billion euros when...

Saia, Inc. (SAIA) Friday announced a decline in fourth-quarter earnings, despite higher revenues, compared to the prior year. Quarterly earnings were $70.86 million, or $2.65 per share, down from $73.76 million or $2.76 per share last year. On average, 16 analysts polled by Thomson Reuters expected...

Drug major Merck & Co. Inc. (MRK) announced Friday that KEYTRUDA plus chemotherapy met primary endpoint of progression-free survival or PFS as first-line therapy for advanced or recurrent Endometrial Carcinoma. Endometrial carcinoma begins in the inner lining of the uterus, which is known as the endometrium,...

Gracell Biotechnologies Inc. (GRCL) announced the FDA has cleared the company's Investigational New Drug application and the company can proceed to initiate a Phase 1b/2 clinical trial in the U.S. of GC012F for the treatment of relapsed/refractory multiple myeloma. The company plans to initiate a Phase...

Zimmer Biomet Holdings Inc. (ZBH) said it expects adjusted earnings per share to be in the range $6.95 - $7.15 and revenue growth of 1.5% - 3.5% for fiscal year 2023. Analysts polled by Thomson Reuters expect the company to report earnings of $6.98 per share for fiscal year 2023. Analysts' estimates...

Regeneron Pharmaceuticals, Inc. (REGN) reported fourth-quarter adjusted profit per share of $12.56 compared to $23.42, prior year. On average, 21 analysts polled by Thomson Reuters expected the company to report profit per share of $10.03, for the quarter. Analysts' estimates typically exclude special...

Boston Scientific Corp. (BSX) said Friday that it has received a 510(k) clearance from the U.S. Food and Drug Administration for the LithoVue Elite Single-Use Digital Flexible Ureteroscope System, the first ureteroscope system with the ability to monitor intrarenal pressure in real-time during ureteroscopy...

Linde (LIN) announced it signed 52 new small on-site projects for the supply of nitrogen and oxygen in 2022, a 21% increase from last year. The company said the increase was largely driven by growing demand for next-generation energy storage, such as lithium-ion batteries. The Small on-site projects...

French drug major Sanofi (SNYNF, SNY) reported Friday that its fourth-quarter net income, on IFRS basis, climbed 29.1 percent to 1.46 billion euros from last year's 1.13 billion euros. Earnings per share grew 29 percent to 1.16 euros from 0.90 euro a year ago. Business net income was 2.14 billion...

Japanese trading and investment firm Mitsui & Co Ltd. (MITSF.PK, MITSY.PK) on Friday reported higher profit and revenues for the nine- month period. Further, the company raised its dividend, as well as earnings forecast for fiscal 2023. For the period, profit attributable to owners of the parent...

Follow RTT